Author

Kirsten Marie Boughan

Observed names: K. Boughan, K.M. Boughan, Kirsten Boughan, Kirsten M Boughan, Kirsten M. Boughan

Institution: Louis Stokes Cleveland VA Medical Center

Observed institutions: Cleveland Clinic, Memorial Sloan Kettering Cancer Center, University Hospitals of Cleveland, Veterans Health Administration, University Hospitals Cleveland Medical Center, Louis Stokes Cleveland VA Medical Center, University Hospitals Seidman Cancer Center, VA Northeast Ohio Healthcare System, Case Comprehensive Cancer Center, The Ohio State University, Case Western Reserve University, Drexel University

OpenAlex ID: A5011076004

Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

2020 · Richard T. Hoppe, Ranjana H. Advani, et al. · Journal of the National Comprehensive Cancer Network · 154

Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

2021 · Andrew M. Evens, Alexey Danilov, et al. · Blood · 123

PDF

Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma

2021 · Paolo F. Caimi, Gabriela Pacheco Sanchez, et al. · Frontiers in Immunology · 121

PDF

Racial disparities in access to HLA-matched unrelated donor transplants: a prospective 1312-patient analysis

2019 · Juliet N. Barker, Kirsten Boughan, et al. · Blood Advances · 109

PDF

HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis

2021 · Juan Pablo Alderuccio, Adam J. Olszewski, et al. · Blood Advances · 51

Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study

2021 · Adam S. Zayac, Andrew M. Evens, et al. · Haematologica · 45

PDF

Socioeconomic Factors and Survival of Multiple Myeloma Patients

2021 · Kamal Chamoun, Amin Firoozmand, et al. · Cancers · 35

PDF

A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult Donors

2022 · Folashade Otegbeye, Brenda Cooper, et al. · Transplantation and Cellular Therapy · 31

PDF

Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma ‐ specific venous thrombosis prediction models

2020 · Gouri Dharmavaram, Shufen Cao, et al. · American Journal of Hematology · 23

PDF

Experimental infection of dairy calves with Ehrlichia chaffeensis

2007 · Jose R. C. delos Santos, Kirsten Boughan, et al. · Journal of Medical Microbiology · 19

Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis

2019 · Adam Zayac, Andrew Matthew Evens, et al. · Blood · 16

Prophylactic Tocilizumab in Patients with Relapsed Refractory Lymphoma Treated with Anti CD19 Chimeric Antigen Receptor T-Cell Therapy

2020 · Nausheen Ahmed, Paolo Caimi, et al. · Transplantation and Cellular Therapy · 14

Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trial

2025 · Armin Ghobadi, Paolo F. Caimi, et al. · EClinicalMedicine · 11

Follicular Lymphoma: Diagnostic and Prognostic Considerations in Initial Treatment Approach

2019 · Kirsten M. Boughan, Paolo F. Caimi · Current Oncology Reports · 10

Risk factors for cardiovascular events and mortality in patients diagnosed with diffuse large B‐cell lymphoma and treated with anthracyclines

2022 · Akiva Diamond, Sabarish Ayyappan, et al. · Hematological Oncology · 8

Phase Ib trial of vactosertib in combination with pomalidomide in relapsed multiple myeloma: A corticosteroid-free approach by targeting TGF-β signaling pathway.

2021 · Ehsan Malek, Sunjin Hwang, et al. · Journal of Clinical Oncology · 8

Safety and Efficacy of Venetoclax Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide Chemoimmunotherapy (VICER) for Treatment of Relapsed Diffuse Large B Cell Lymphoma: Results from the Phase 1 Study

2018 · Paolo Caimi, Deepa Jagadeesh, et al. · Blood · 8

Targeted Marrow Irradiation Intensification of Reduced-Intensity Fludarabine/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation

2022 · Naveed Ali, Ashish Arunkumar Sharma, et al. · Transplantation and Cellular Therapy · 7

A Renal Mass in a Patient With Melanoma

2009 · Kirsten M. Boughan, Sebouh Setrakian, et al. · Clinical Genitourinary Cancer · 7

Preclinical Studies and Phase I Trial of Vactosertib in Combination with Pomalidomide in Relapsed Multiple Myeloma: A Corticosteroid-Free Approach By Targeting TGF-β Signaling Pathway

2019 · Ehsan Malek, Sunjin Hwang, et al. · Blood · 6

Diffuse Large B Cell Lymphoma in Patients 80 Years and Older: Worse Survival After Treatment Without Increased Relapse Rates

2021 · Madison Keenan, Akiva Diamond, et al. · Clinical Lymphoma Myeloma & Leukemia · 5

Risk of Secondary Malignancy in CLL Patients Treated with Novel Targeted Agents

2020 · Anna Eversman, Shufen Cao, et al. · Blood · 5

Circulating Tumor DNA Correlation with Lymphoma Response and Survival Outcomes at Multiple Time Points of Anti - CD19 CAR T Cell Therapy

2022 · Paolo F Caimi, Martina Di Trani, et al. · Blood · 4

The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)

2019 · Andrew M. Evens, Alexey Danilov, et al. · Blood · 4

Phase 1 trial of anti-CD19 chimeric antigen receptor T (CAR-T) cells with tumor necrosis alfa receptor superfamily 19 (TNFRSF19) transmembrane domain.

2019 · Paolo Fabrizio Caimi, Jane Reese, et al. · Journal of Clinical Oncology · 4

Works count: 74

Citation count: 871

H-index: 12

I10-index: 14